Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Baker J, Sarraju A, Singh S, Wang Q, Wolski K, Xu H, Nielsen J, Patel N, Duran JM, Nissen SE.
Laffin LJ, et al.
N Engl J Med. 2025 Nov 27;393(21):2119-2130. doi: 10.1056/NEJMoa2511778. Epub 2025 Nov 8.
N Engl J Med. 2025.
PMID: 41211945
Clinical Trial.